Neuropharmacological treatments for alcoholism: scientific basis and clinical findings

被引:123
作者
Johnson, BA [1 ]
Ait-Daoud, N
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Psychiat & Pharmacol, San Antonio, TX 78284 USA
[2] Univ Texas, Dept Psychiat, San Antonio, TX 78212 USA
关键词
alcohol; treatment; medications; ondansetron; acamprosate; naltrexone; nalmefene; ritanserin; SSRI; fluoxetine;
D O I
10.1007/s002130000371
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Preclinical studies have exploded our knowledge about the behavioral and biological underpinnings of alcoholism. These studies suggest that certain neurotransmitters, particularly those interacting with the opioid, N-methyl-D-aspartate, and monoamine systems, may play a critical role in the expression of alcohol-drinking and other behaviors associated with its abuse liability. Built upon this foundation, important advances have been made in the development of therapeutic medications for the treatment of alcoholism. Of the medications reviewed, acamprosate's potential appears to be the most widely established. In the USA, naltrexone was approved by the Food and Drug Administration in 1995 for the treatment of alcoholism; however, the results of some studies have been less encouraging. Naltrexone's reliance on high compliance rates for efficacy may, eventually, limit its potential in clinical settings offering generic treatment for alcoholism. The relative paucity of dose-response studies on naltrexone's effects in treating alcoholics is an important gap in the literature. Recent data from a large clinical trial suggests that ondansetron, a serotonin, antagonist, offers new hope for the treatment of early onset alcoholics; a type of alcoholism most difficult to manage with psychosocial measures alone. Different subtypes of alcoholic may, therefore, have varying treatment responses to serotonergic agents. Matching subtypes of alcoholic to effective treatment medications based upon their different biologies remains an important therapeutic goal. Combinations of effective pharmacological agents need exploration as they may prove to be synergistic, and could shepherd in a new era of treatments aimed at multiple neurotransmitter targets associated with the alcoholism disease. The coming decade promises more powerful tools for characterizing drug effects on alcohol drinking, thereby closing the gap be tween animal models of addiction and the human condition.
引用
收藏
页码:327 / 344
页数:18
相关论文
共 218 条
[1]
Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex [J].
al Qatari, M ;
Bouchenafa, O ;
Littleton, J .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1998, 22 (04) :810-814
[2]
ALTERATION OF ETHANOL SELF-ADMINISTRATION BY NALTREXONE [J].
ALTSHULER, HL ;
PHILLIPS, PE ;
FEINHANDLER, DA .
LIFE SCIENCES, 1980, 26 (09) :679-688
[3]
[Anonymous], 1993, Alcohol Clin Exp Res, V17, P1130
[4]
Anton RF, 1999, AM J PSYCHIAT, V156, P1758
[5]
PHARMACOLOGICAL PROFILE OF RITANSERIN - A VERY SPECIFIC CENTRAL SEROTONIN S2-ANTAGONIST [J].
AWOUTERS, F ;
NIEMEGEERS, CJE ;
MEGENS, AAHP ;
MEERT, TF ;
JANSSEN, PAJ .
DRUG DEVELOPMENT RESEARCH, 1988, 15 (01) :61-73
[6]
BALLENGER JC, 1979, ARCH GEN PSYCHIAT, V36, P224
[7]
A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[8]
SEROTONIN 5-HT3 ANTAGONISTS FAIL TO AFFECT ETHANOL SELF-ADMINISTRATION OF RATS [J].
BEARDSLEY, PM ;
LOPEZ, OT ;
GULLIKSON, G ;
FLYNN, D .
ALCOHOL, 1994, 11 (05) :389-395
[9]
NALTREXONE REVERSES ETHANOL-INDUCED DOPAMINE RELEASE IN THE NUCLEUS-ACCUMBENS IN AWAKE, FREELY MOVING RATS [J].
BENJAMIN, D ;
GRANT, ER ;
POHORECKY, LA .
BRAIN RESEARCH, 1993, 621 (01) :137-140
[10]
EFFECTS OF NALOXONE ON ETHANOL DEPENDENCE IN RATS [J].
BERMAN, RF ;
LEE, JA ;
OLSON, KL ;
GOLDMAN, MS .
DRUG AND ALCOHOL DEPENDENCE, 1984, 13 (03) :245-254